Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Ondrej Bilek"'
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 9 (2021)
Parylene-based implants or coatings introduce surfaces suffering from bacteria colonization. Here, we synthesized polyvinylpyrrolidone-stabilized selenium nanoparticles (SeNPs) as the antibacterial agent, and various approaches are studied for their
Externí odkaz:
https://doaj.org/article/1e457a07e9a54e70b30955058fba3f31
Autor:
Milos Holanek, Iveta Selingerova, Pavel Fabian, Oldrich Coufal, Ondrej Zapletal, Katarina Petrakova, Tomas Kazda, Roman Hrstka, Alexandr Poprach, Maria Zvarikova, Ondrej Bilek, Marek Svoboda
Publikováno v:
Diagnostics, Vol 12, Iss 7, p 1740 (2022)
A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecut
Externí odkaz:
https://doaj.org/article/683bdd4ed2e2407987165083b0d972a6
Autor:
Milos Holanek, Iveta Selingerova, Ondrej Bilek, Tomas Kazda, Pavel Fabian, Lenka Foretova, Maria Zvarikova, Radka Obermannova, Ivana Kolouskova, Oldrich Coufal, Katarina Petrakova, Marek Svoboda, Alexandr Poprach
Publikováno v:
Cancers, Vol 13, Iss 7, p 1586 (2021)
Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a m
Externí odkaz:
https://doaj.org/article/705e0daa58fc46d2bc23b87a1e6fe6d9
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0214066 (2019)
Selenium nanoparticle modified surfaces attract increasing attention in the field of tissue engineering. Selenium exhibits strong anticancer, antibacterial and anti-inflammatory properties and it maintains relatively low off-target cytotoxicity. In o
Externí odkaz:
https://doaj.org/article/6a438aef62614fb4a67fb38dae24b036
Autor:
Michal Sedlacik, Alena Ronzova, Andrei Munteanu, Erika Kutalkova, Petra Drohsler, Robert Moucka, Milan Kracalik, Ondrej Bilek, Saiful Amri Mazlan
Publikováno v:
Scientific Reports
Despite the vast amount of studies based on magnetorheological elastomers (MREs), a very limited number of investigations have been initiated on their reprocessing. This paper presents a new type of recyclable MRE which is composed of thermoplastic p
Autor:
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA, MAREK STASTNY
Publikováno v:
Anticancer research. 42(4)
This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens.The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treate
Autor:
Magda Barinova, Bohuslav Melichar, Karolina Hurdalkova, Martin Svaton, Jiri Blazek, Lenka Jakubíková, M. Černovská, Michal Jirousek, Daniel Krejci, Jana Skrickova, Milada Zemanova, J. Krejčí, Petra Zemanova, Michal Hrnčiarik, Ondrej Bilek, Ondrej Fischer, Juraj Kultan
Publikováno v:
Anticancer Research. 40:2209-2217
To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung can
Autor:
Ondrej Bilek, Zdenka Fohlerova, Kristyna Smerkova, Tatiana Fialova, Alexandr Otahal, Vojtech Adam
Publikováno v:
RSC Advances. 2020, vol. 10, issue 72, p. 1-10.
Enhanced antibacterial properties of nanomaterials such as TiO2 nanotubes (TNTs) and silver nanoparticles (AgNPs) have attracted much attention in biomedicine and industry. The antibacterial properties of nanoparticles depend, among others, on the fu
Autor:
Jan Jurica, Jiri Vasina, Lenka Zdrazilova-Dubska, Tomas Kazda, Iveta Selingerová, Alexandr Poprach, Simona Borilova, Ondrej Bilek, Miloš Holánek, Sona Stepankova, Igor Kiss
Publikováno v:
International immunopharmacology. 99
ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the
Autor:
Iveta Selingerová, Tomas Kazda, Ivana Kolouskova, Katarína Petráková, Miloš Holánek, Oldrich Coufal, Ondrej Bilek, Radka Obermannova, Lenka Foretova, Pavel Fabian, Marek Svoboda, Alexandr Poprach, Mária Zvaríková
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1586, p 1586 (2021)
Volume 13
Issue 7
Cancers, Vol 13, Iss 1586, p 1586 (2021)
Volume 13
Issue 7
Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a m